

## Special Issue

# Personalized Gastric Cancer Treatment: Recent Progress and Future Perspectives

### Message from the Guest Editor

The treatment paradigm in patients with gastric cancer has changed drastically in recent years. In the metastatic setting, based on biomarker testing, we have many approved combination regimens in the first-line setting, including agents targeting HER2 (e.g., trastuzumab), CLDN18.2 (e.g., zolbetuximab), PD-L1 CPS (e.g., pembrolizumab, nivolumab, and tislelizumab), and MSI-H (e.g., pembrolizumab, nivolumab/ipilimumab, and dostarlimab). In the perioperative setting, we are seeing positive results with moving agents to earlier stages, as shown in the recently reported MATTERHORN study where durvalumab was combined with systemic chemotherapy. Despite our success, there remains an unmet need to improve outcomes for patients, as our current treatments risk high recurrence rates, toxicity, and persistently low survival outcomes. Therefore, this Special Issue aims to collate high-quality studies, including original research and reviews, exploring the association of biomarkers with gastric cancer outcomes.

### Guest Editor

Dr. Gagandeep Brar

Division of Hematology & Oncology, City of Hope, Duarte, CA 91010, USA

### Deadline for manuscript submissions

10 August 2026



## Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/255102](https://mdpi.com/si/255102)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine* is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).